Skip to Content

Alkermes PLC ALKS

Morningstar Rating
$30.24 +0.55 (1.85%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ALKS is trading at a 17% discount.
Price
$30.17
Fair Value
$94.72
Uncertainty
Very High
1-Star Price
$68.36
5-Star Price
$79.43
Economic Moat
Fwwyr
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALKS is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$29.69
Day Range
$29.6430.35
52-Week Range
$22.0133.71
Bid/Ask
$30.18 / $30.50
Market Cap
$5.05 Bil
Volume/Avg
1.8 Mil / 2.8 Mil

Key Statistics

Price/Earnings (Normalized)
18.00
Price/Sales
3.09
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Growth
Total Number of Employees
2,100

Competitors

Valuation

Metric
ALKS
JNJ
Price/Earnings (Normalized)
18.0015.54
Price/Book Value
4.205.67
Price/Sales
3.094.87
Price/Cash Flow
11.7220.46
Price/Earnings
ALKS
JNJ

Financial Strength

Metric
ALKS
JNJ
Quick Ratio
2.130.91
Current Ratio
2.861.16
Interest Coverage
17.9618.88
Quick Ratio
ALKS
JNJ

Profitability

Metric
ALKS
JNJ
Return on Assets (Normalized)
18.90%13.98%
Return on Equity (Normalized)
33.67%35.02%
Return on Invested Capital (Normalized)
24.95%22.24%
Return on Assets
ALKS
JNJ
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
ZTS
Zoetis Inc Class AVjv$87.4 Bil
MKKGY
Merck KGaA ADRPprgb$74.3 Bil
HLN
Haleon PLC ADRXblw$38.5 Bil
VTRS
Viatris IncZyfl$15.1 Bil
RDY
Dr Reddy's Laboratories Ltd ADRRpjs$12.4 Bil
CTLT
Catalent IncRfsclb$10.3 Bil
CURLF
Curaleaf Holdings IncMfk$3.6 Bil
PRGO
Perrigo Co PLCZjdl$3.6 Bil
PBH
Prestige Consumer Healthcare IncSdfjsvw$3.5 Bil
GTBIF
Green Thumb Industries IncSvyz$3.1 Bil

Sponsor Center